CSI Market
Sign In | Register

Aspire Biopharma Holdings Inc (ASBP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ASBP Annual Cash Flow →
Quarterly cash flow trends provide additional context on Aspire Biopharma Holdings Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-4.49
Depreciation & amortization0.00
Amortization of Other Assets1.58
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.12
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.16
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt1.12
Investment Income Interest-
Proceeds From Subscription Receivable-
Note Payable Addition From Oid-
Interest Expense Debt-
Loss On Extinguishment Of Debt0.24
Interest Expense-
Derivative Gain Loss On Derivative Net-0.25
Interest Costs Capitalized0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Due from Related Parties0.00
Increase (Decrease) in Accounts Payable-0.01
Increase (Decrease) in Accrued Liabilities-0.04
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.95
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.54
Discontinued operations0.00
Net Cash flow from Operating Activities-5.15
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Cash Withdrawn From Trust Account In Connection With Redemptions-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net-0.17
Other borrowing transactions-0.08
Long-term debt - borrowings0.00
Long-term debt - repayments-1.38
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock17.95
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Net Proceeds From Initial Public Offering-
Repayment Of Notes Payable To Related Parties-
Proceeds From Loan And Transfer Payable-
Short Term Loan From Shareholders-
Repayment Of Subscription Agreement Loan-
Transaction Costs Paid In Connection With Convertible Notes-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities16.32
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.15
Total Cash Flow11.16
4 historic quarters locked

Sign in to unlock the full Aspire Biopharma Holdings Inc cash flow history.

Sign In Create Free Account

About Aspire Biopharma Holdings Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037819

Figures are derived from filed reports and may be restated. Historical data is subject to revision.